{"commentary":{"count":6,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":2,"podcast":2,"x_thread":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"CLOVER-WaM","nct_id":"NCT02952508","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=clover-wam-nct02952508. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"CLOVER-WaM","arms":[{"description":"Iopofosine I 131 in Waldenstroms Macroglobulinemia","label":"Iopofosine I 131, intravenous administration WM","type":"EXPERIMENTAL"},{"description":"Iopofosine I 131 in Multiple Myeloma","label":"Iopofosine I 131, intravenous administration MM","type":"EXPERIMENTAL"},{"description":"Iopofosine I 131 in Central Nervous System Lymphoma","label":"Iopofosine I 131, intravenous administration CNS Lymphoma","type":"EXPERIMENTAL"},{"description":"Iopofosine I 131 in Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, and Diffuse Large B-Cell Lymphoma","label":"Iopofosine I 131 intravenous administration NHL [CLOSED]","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-12-22","type":"ESTIMATED"},"conditions":["Waldenstrom Macroglobulinemia","Multiple Myeloma","Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma","Lymphoplasmacytic Lymphoma","Marginal Zone Lymphoma","Mantle Cell Lymphoma","Diffuse Large B Cell Lymphoma","Central Nervous System Lymphoma"],"enrollment":{"count":120,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Iopofosine I 131 single dose","type":"DRUG"},{"name":"Iopofosine I 131 multiple dose","type":"DRUG"},{"name":"Iopofosine I 131 fractionated dose","type":"DRUG"}],"last_update":"2026-03-18","lead_sponsor":"Cellectar Biosciences, Inc.","official_title":"An Open-Label, Multicenter, Phase 2 Study of Iopofosine I 131 (CLR 131) in Patients With Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients With Waldenstrom Macroglobulinemia (CLOVER-WaM)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-06-22","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Part A [CLOVER-1] Clinical benefit rate","timeFrame":"84 days"},{"measure":"Part B [CLOVER-WaM] Major Response Rate","timeFrame":"12 months"}],"references":[],"start_date":{"date":"2017-07-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom","url":"https://clinicaltrials.gov/study/NCT02952508"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/clover-wam-nct02952508"}